Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo Nordisk Halts AERx Development, But Not Giving Up On All Inhaled Insulin

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Novo Nordisk is halting development of its Phase III AERx inhaled insulin product after determining it would not offer measurable benefit over currently available pen injection devices, the Danish firm announced Jan. 14

You may also be interested in...



Lilly Drops Inhaled Insulin With Alkermes; Will MannKind Make Giant Leap?

Lilly is the third company to drop development of inhaled insulin, citing "increasing uncertainties in the regulatory environment" and evaluation of commercial and clinical potential. Novo Nordisk also dropped its fast-acting inhaled insulin AERx after Pfizer discontinued pioneer Exubera. MannKind CEO talks up advantages of its Technosphere product, still trying to make a go of the market

Lilly Drops Inhaled Insulin With Alkermes; Will MannKind Make Giant Leap?

Lilly is the third company to drop development of inhaled insulin, citing "increasing uncertainties in the regulatory environment" and evaluation of commercial and clinical potential. Novo Nordisk also dropped its fast-acting inhaled insulin AERx after Pfizer discontinued pioneer Exubera. MannKind CEO talks up advantages of its Technosphere product, still trying to make a go of the market

Lilly/Daiichi On Track For Prasugrel NDA By Year End, Despite Mixed Results

Lilly and Daiichi Sankyo are on track to submit an NDA for their experimental antiplatelet drug prasugrel by the end of the year despite mixed study results that showed it is more effective than Plavix but with a worrisome bleeding profile.

Topics

UsernamePublicRestriction

Register

PS003775

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel